|
1.
|
Bosch FX and de Sanjosé S: Chapter 1:
Human papillomavirus and cervical cancer - burden and assessment of
causality. J Natl Cancer Inst Monogr. 31:3–13. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Parkin DM, Pisani P and Ferlay J: Global
cancer statistics. CA Cancer J Clin. 49:33–64. 1999. View Article : Google Scholar
|
|
3.
|
Rana TM: Illuminating the silence:
understanding the structure and function of small RNAs. Nat Rev Mol
Cell Biol. 8:23–36. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Filipowicz W, Bhattacharyya SN and
Sonenberg N: Mechanisms of post-transcriptional regulation by
microRNAs: are the answers in sight? Nat Rev Genet. 9:102–114.
2008. View
Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Bartel DP: MicroRNAs: genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Rao PH, Houldsworth J, Dyomina K, et al:
Chromosomal and gene amplification in diffuse large B-cell
lymphoma. Blood. 92:234–240. 1998.PubMed/NCBI
|
|
7.
|
Ota A, Tagawa H, Karnan S, et al:
Identification and characterization of a novel gene, C13orf25, as a
target for 13q31–q32 amplification in malignant lymphoma. Cancer
Res. 64:3087–3095. 2004.
|
|
8.
|
Tagawa H and Seto M: A microRNA cluster as
a target of genomic amplification in malignant lymphoma. Leukemia.
19:2013–2016. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Olive V, Bennett MJ, Walker JC, Ma C, et
al: miR-19 is a key oncogenic component of mir-17-92. Genes Dev.
23:2839–2849. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Zhang X, Yu H, Lou JR, Zheng J, et al:
MicroRNA-19 (miR-19) regulates tissue factor expression in breast
cancer cells. J Biol Chem. 286:1429–1435. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Cho WC, Chow AS and Au JS: Restoration of
tumour suppressor hsa-miR-145 inhibits cancer cell growth in lung
adenocarcinoma patients with epidermal growth factor receptor
mutation. Eur J Cancer. 45:2197–2206. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Eades G, Yang M, Yao Y, Zhang Y and Zhou
Q: miR-200a regulates Nrf2 activation by targeting Keap1 mRNA in
breast cancer cells. J Biol Chem. 286:40725–40733. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Xiao C, Srinivasan L, Calado DP, Patterson
HC, Zhang B, Wang J, et al: Lymphoproliferative disease and
autoimmunity in mice with increased miR-17-92 expression in
lymphocytes. Nat Immunol. 9:405–414. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Bonneau D and Longy M: Mutations of the
human PTEN gene. Hum Mutat. 16:109–122. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Petrocelli T and Slingerland JM: PTEN
deficiency: a role in mammary carcinogenesis. Breast Cancer Res.
3:356–360. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Byun D, Cho K, Ryu B, et al: Frequent
monoallelic deletion of PTEN and its reciprocal association with
PIK3CA amplification in gastric carcinoma. Int J Cancer.
104:318–327. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Farazi TA, Spitzer JI, Morozov P and
Tuschl T: miRNAs in human cancer. J Pathol. 223:102–115. 2011.
View Article : Google Scholar
|
|
18.
|
Shigoka M, Tsuchida A, Matsudo T, et al:
Deregulation of miR-92a expression is implicated in hepatocellular
carcinoma development. Pathol Int. 60:351–357. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Al-Nakhle H, Burns PA, Cummings M, et al:
Estrogen receptor (beta)1 expression is regulated by miR-92 in
breast cancer. Cancer Res. 70:4778–4784. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Wang X, Tang S, Le SY, Lu R, Rader JS,
Meyers C and Zheng ZM: Aberrant expression of oncogenic and
tumor-suppressive microRNAs in cervical cancer is required for
cancer cell growth. PLoS One. 3:e25572008. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Li B, Hu Y, Ye F, Li Y, Lv W and Xie X:
Reduced miR-34a expression in normal cervical tissues and cervical
lesions with high-risk human papillomavirus infection. Int J
Gynecol Cancer. 20:597–604. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Brosh R, Shalgi R, Liran A, Landan G,
Korotayev K, Nguyen GH, Enerly E, Johnsen H, Buganim Y, et al:
p53-Repressed miRNAs are involved with E2F in a feed-forward loop
promoting proliferation. Mol Syst Biol. 4:2292008. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Li Y, Wang F, Xu J, Ye F, Shen Y, Zhou J,
Lu W, Wan X, Ma D and Xie X: Progressive miRNA expression profiles
in cervical carcinogenesis and identification of HPV-related target
genes for miR-29. J Pathol. 224:484–495. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Rao Q, Shen Q, Zhou H, Peng Y, Li J and
Lin Z: Aberrant microRNA expression in human cervical carcinomas.
Med Oncol. 29:1242–1248. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Au Yeung CL, Tsang TY, Yau PL and Kwok TT:
Human papillomavirus type 16 E6 induces cervical cancer cell
migration through the p53/microRNA-23b/urokinase-type plasminogen
activator pathway. Oncogene. 30:2401–2410. 2011.PubMed/NCBI
|
|
26.
|
Zheng ZM: Viral oncogenes, noncoding RNAs,
and RNA splicing in human tumor viruses. Int J Biol Sci. 6:730–755.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Narisawa-Saito M and Kiyono T: Basic
mechanisms of high-risk human papillomavirus-induced
carcinogenesis: roles of E6 and E7 proteins. Cancer Sci.
98:1505–1511. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
McLaughlin-Drubin ME and Münger K: The
human papillomavirus E7 oncoprotein. Virology. 384:335–344. 2009.
View Article : Google Scholar : PubMed/NCBI
|
